If clinical improvement is not observed after treatment with 16 mg per day for at least 10 days, symptoms are unlikely to be controlled by further administration. Loperamide hydrochloride capsules administration may be continued if diarrhea cannot be adequately controlled with diet or specific treatment. The use of loperamide hydrochloride in children under 2 years is not recommended. There have been rare reports of paralytic ileus associated with abdominal distention. Most of these reports occurred in the setting of acute dysentery, overdose, and with very young children less than two years of age.

No formal pharmacokinetic studies were conducted in elderly subjects. However, there were no major differences in the drug disposition in elderly patients with diarrhea relative to young patients. No dosage adjustment is required for the elderly. No pharmacokinetic data are available in patients with renal impairment.

Loperamide hydrochloride capsules USP, 2 mg are available as: A light brown opaque body and dark brown opaque capsule, imprinted "93"-"" and packaged in bottles of and Dispense in a well-closed container, as defined in the USP, with a child-resistant closure as required.

Sellersville, PA Rev. Qualitative and quantitative composition Each capsule contains 2mg Loperamide hydrochloride. Excipient with known effect: Pharmaceutical form Hard gelatin capsule — green and dark grey. For the symptomatic treatment of acute episodes of diarrhoea associated with Irritable Bowel Syndrome in adults aged 18 years and over following initial diagnosis by a doctor.

Adults and children over Two capsules 4 mg initially, followed by one capsule 2 mg after each loose stool. The usual dose is capsules 6 mg — 8 mg a day. The total daily dose should not exceed 6 capsules 12 mg. Symptomatic treatment of acute episodes of diarrhoea associated with irritable bowel syndrome in adults aged 18 and over Two capsules 4 mg to be taken initially, followed by 1 capsule 2 mg after every loose stool, or as previously advised by your doctor.

The maximum daily dose should not exceed 6 capsules 12 mg. Paediatric population Loperamide hydrochloride is contraindicated in children less than 12 years of age. Elderly No dose adjustment is required for the elderly. Renal Impairment No dose adjustment is required for patients with renal impairment. Hepatic Impairment Although no pharmacokinetic data are available in patients with hepatic impairment, loperamide hydrochloride should be used with caution in such patients because of reduced first pass metabolism see section 4.

Method of administration Oral use. The capsules should be taken with liquid. Loperamide hydrochloride must not be used when inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon.

Loperamide must be discontinued promptly when ileus, constipation or abdominal distension develop. Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with nifedipine, a mild P-gp inhibitor. Major Loperamide should be avoided in combination with nilotinib. Nilotinib also prolongs the QT interval and the manufacturer advises against use with other drugs that prolong the QT interval.

If concurrent administration is unavoidable, the manufacturer of nilotinib recommends interruption of nilotinib treatment. If nilotinib must be continued, closely monitor the patient for QT interval prolongation. In addition, if these drugs are used together, the plasma concentrations of loperamide may increase. Nilotinib is an inhibitor of all 4 enzymes and P-gp, further increasing the risk of toxicity.

Monitor for cardiac toxicities i. Moderate Loperamide should be used cautiously and with close monitoring with norfloxacin. Quinolones have been associated with a risk of QT prolongation and TdP. Although extremely rare, torsade de pointes has been reported during post-marketing surveillance of norfloxacin.

These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. Moderate Loperamide should be used cautiously and with close monitoring with octreotide. Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy. Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval.

In addition, the plasma concentrations of loperamide, a CYP3A4 substrate, may be increased when administered concurrently with octreotide, a CYP3A4 inhibitor. Drugs with a possible risk for QT prolongation and TdP, like ofloxacin, should be used cautiously and with close monitoring with loperamide Olanzapine: Major Coadminister loperamide and ondansetron together with caution and monitor the ECG. Ondansetron has also been associated with an increased risk of QT prolongation and TdP.

Risk for QT prolongation increases with increased dosage, and a 32 mg IV dose of ondansetron must no longer be used for the prevention of chemotherapy-induced nausea and vomiting. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with oritavancin. Major Monitor electrolytes and ECGs for QT prolongation if coadministration of loperamide with osimertinib is necessary; an interruption of osimertinib therapy and dose reduction may be necessary if QT prolongation occurs.

Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. Major Monitor electrolytes and ECGs for QT prolongation if coadministration of loperamide with oxaliplatin is necessary; correct electrolyte abnormalities prior to administration of oxaliplatin.

QT prolongation and ventricular arrhythmias including fatal TdP have also been reported with oxaliplatin use in postmarketing experience. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with oxcarbazepine.

Loperamide is metabolized by the hepatic enzyme CYP3A4; oxcarbazepine is an inducer of this enzyme. Moderate Both antidiarrheals and anticholinergics, such as oxybutynin, decrease GI motility. Major Loperamide should be avoided in combination with paliperidone. Paliperidone has been associated with QT prolongation. According to the manufacturer, since paliperidone may prolong the QT interval, it should be avoided in combination with other agents also known to have this effect. If coadministration is considered necessary by the practitioner, and the patient has known risk factors for cardiac disease or arrhythmia, then close monitoring is essential.

In addition, the plasma concentrations of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with paliperidone, a weak P-gp inhibitor, further increasing the risk of toxicity. Major Loperamide should be avoided in combination with panobinostat. QT prolongation has been reported with panobinostat therapy in patients with multiple myeloma in a clinical trial; use of panobinostat with other agents that prolong the QT interval is not recommended.

If coadministration cannot be avoided, obtain an electrocardiogram at baseline and periodically during treatment. In addition, the plasma concentrations of loperamide, a CYP2D6 substrate, may be increased when administered concurrently with panobinostat, a potent CYP2D6 inhibitor, further increasing the risk of toxicity. Drugs with a possible risk for QT prolongation and TdP, like pasireotide, should be used cautiously and with close monitoring with loperamide.

Major Loepramide should be avoided in combination with pazopanib. Coadministration of pazopanib and other drugs that prolong the QT interval is not advised; pazopanib has been reported to prolong the QT interval. If pazopanib and loperamide must be continued, closely monitor the patient for QT interval prolongation. In addition, if these drugs are used together, the plasma concentrations of loperamide may increase, further increasing the risk of toxicity.

Drugs with a possible risk for QT prolongation and TdP, like pentamidine, should be used cautiously and with close monitoring with loperamide. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with perampanel. Loperamide is metabolized by the hepatic enzyme CYP3A4; perampanel is a mild inducer of this enzyme.

Minor Perphenazine is associated with a possible risk for QT prolongation. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with drugs with a risk of QT prolongation. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with topiramate.

Loperamide is metabolized by the hepatic enzyme CYP3A4; topiramate is a mild inducer of this enzyme. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with phenytoin.

Major Pimavanserin should be avoided in combination with loperamide. Pimavanserin may cause QT prolongation; high doses of loperamide have been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes TdP , and cardiac arrest. Severe Pimozide is associated with a well-established risk of QT prolongation and torsade de pointes TdP. Severe The concurrent use of posaconazole with drugs that are associated with QT prolongation and are also CYP3A4 substrates, such as loperamide, is contraindicated.

Posaconazole has been associated with prolongation of the QT interval as well as rare cases of torsade de pointes TdP ; at high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest. If these drugs were administered together, the plasma concentrations of loperamide, a CYP3A4 substrate and P-glycoprotein P-gp substrate, may be increased by posaconazole, an inhibitor of CYP3A4 and P-gp, further increasing the risk of cardiac toxicities.

Potassium Phosphate; Sodium Phosphate: Major Pramlintide slows gastric emptying and the rate of nutrient delivery to the small intestine. Medications with the potential to slow GI motility such as loperamide, should be used with caution, if at all, with pramlintide until more data are available from the manufacturer.

Drugs with a possible risk for QT prolongation and TdP, like primaquine, should be used cautiously and with close monitoring with loperamide. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with primidone.

Drugs with a possible risk for QT prolongation and TdP, like procainamide, should be used cautiously and with close monitoring with loperamide.

Minor Prochlorperazine is associated with a possible risk for QT prolongation. Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with drugs with a risk of QT prolongation. Major Loperamide should be used cautiously and with close monitoring with propafenone. In addition, the plasma concentrations of loperamide, a CYP2D6 and P-glycoprotein P-gp substrate, may be increased when administered concurrently with propafenone, a potent CYP2D6 and P-gp inhibitor, further increasing the risk of toxicity.

Major Avoid coadministration of Loperamide and Quetiapine if possible. Limited data suggest that quetiapine is associated with a significant prolongation of the QTc interval. Major Loperamide should be avoided in combination with quinine. Quinine has been associated with QT prolongation and rare cases of torsade de pointes TdP. Avoid concurrent use of quinine with other drugs that may cause QT prolongation and TdP.

If coadministration cannot be avoided, monitor for cardiac toxicities i. Moderate Due to the risk for adverse effects, caution is advised when administering loperamide with ranitidine.

Taking these drugs together may increase the serum concentration of loperamide. Major Coadministration of loperamide with ranolazine may increase the risk for QT prolongation and torsade de pointes TdP. Ranolazine is also associated with dose- and plasma concentration-related increases in the QTc interval. Moderate Loperamide should be used cautiously and with close monitoring with regadenoson. Regadenoson has been associated with QT prolongation and high doses of loperamide have been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes TdP , and cardiac arrest.

Moderate Use caution if coadministration of regorafenib with loperamide is necessary, and monitor for an increase in loperamide-related adverse reactions including cardiac toxicities i. Exposure to loperamide may increase. Major Avoid coadministration of ribociclib with loperamide due to an increased risk for QT prolongation and torsade de pointes TdP. Systemic exposure of loperamide may also be increased resulting in increase in treatment-related adverse reactions.

Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Concomitant use may increase the risk for QT prolongation.

Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with rifabutin. Loperamide is metabolized by the hepatic enzyme CYP3A4; rifabutin is an inducer of this enzyme. Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with rifapentine. Major Both loperamide and risperidone are associated with a possible risk for QT prolongation and torsade de pointes TdP and should be coadministered with caution and close monitoring.

Reports of QT prolongation and TdP during risperidone therapy have occurred primarily in the overdosage setting.

Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with rivaroxaban, a mild P-gp inhibitor. Major Concurrent administration of loperamide and rolapitant may increase the risk for loperamide-associated adverse reactions, such as CNS events and cardiac toxicities i. Romidepsin also prolongs the QT interval. If these drugs are coadministered, appropriately monitor cardiovascular parameters including electrolytes and ECGs.

Moderate Caution is advised with the concomitant use of sapropterin and loperamide as coadministration may result in increased systemic exposure of loperamide. Loperamide is a substrate for the drug transporter P-glycoprotein P-gp ; in vitro data show that sapropterin may inhibit P-gp. If these drugs are used together, closely monitor for increased side effects of loperamide.

Major Saquinavir boosted with ritonavir increases the QT interval in a dose-dependent fashion, which may increase the risk for serious arrhythmias such as torsades de pointes TdP. Avoid administering saquinavir boosted with ritonavir concurrently with other drugs that may prolong the QT interval, such as loperamide.

If no acceptable alternative therapy is available, perform a baseline ECG prior to initiation of concomitant therapy and carefully follow monitoring recommendations. In addition, use of these drugs together may result in elevated loperamide concentrations and a 54 percent decrease in saquinavir exposure.

Predictions about this interaction can be made based on the drugs metabolic pathways. Moderate Coadministration of loperamide with sertraline may increase the risk for QT prolongation and torsade de pointes TdP.

There have been post-marketing reports of QT prolongation and torsade de pointes TdP during treatment with sertraline. In addition, the plasma concentrations of loperamide, a CYP2D6 substrate, may be increased when administered concurrently with sertraline, a weak CYP2D6 inhibitor, further increasing the risk of toxicity.

Moderate Plasma concentrations of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with voxilaprevir, a P-gp inhibitor. Monitor patients for increased side effects if these drugs are administered concurrently.

Moderate Loperamide should be used cautiously and with close monitoring with solifenacin. Solifenacin has been associated with dose-dependent prolongation of the QT interval. TdP has been reported with post-marketing use, although causality was not determined. This should be taken into consideration when prescribing solifenacin to patients taking other drugs that are associated with QT prolongation.

Major Loperamide should be used cautiously and with close monitoring with sorafenib. Sorafenib has also been associated with QT prolongation.

If sorafenib and loperamide must be coadministered, ECG monitoring is recommended; closely monitor the patient for QT interval prolongation. Loperamide is a substrate for the drug transporter P-glycoprotein P-gp. Drugs with a possible risk for QT prolongation and TdP, like sotalol, should be used cautiously and with close monitoring with loperamide. John's Wort, Hypericum perforatum: Moderate The plasma concentration and efficacy of loperamide may be reduced when administered concurrently with St.

John's Wort, Hypericum perforatum. Moderate If these drugs are used together, the plasma concentrations of loperamide may increase. Loperamide is a substrate for CYP2C8. Trimethoprim has been shown in vitro and in studies of healthy human volunteers to selectively inhibit the CYP2C8 isoenzyme. QT prolongation resulting in ventricular tachycardia and torsade de pointes TdP have been reported during post-marketing use of sulfamethoxazole; trimethoprim, SMX-TMP, cotrimoxazole.

Drugs with a possible risk for QT prolongation and TdP, like sunitinib, should be used cautiously and with close monitoring with loperamide. Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with suvorexant, a P-gp inhibitor. Drugs with a possible risk for QT prolongation and TdP, like tacrolimus, should be used cautiously and with close monitoring with loperamide.

Moderate Caution is advised with the concomitant use of tamoxifen with loperamide due to an increased risk of QT prolongation and torsade de pointes TdP ; increased loperamide exposure is also possible. Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used in high doses. Rare case reports of QT prolongation have also been described when tamoxifen is used at lower doses. Tamoxifen may increase exposure to loperamide via inhibition of P-glycoprotein P-gp. Moderate Additive constipation may be seen with concurrent use of tapentadol and antidiarrheals.

Moderate Close clinical monitoring is advised when administering loperamide with telaprevir due to an increased potential for loperamide-related adverse events. If loperamide dose adjustments are made, re-adjust the dose upon completion of telaprevir treatment. Although this interaction has not been studied, predictions about the interaction can be made based on the metabolic pathway of loperamide.

Loperamide is a substrate of the drug efflux transporter P-glycoprotein PGP and of the hepatic isoenzyme CYP3A4; telaprevir is an inhibitor of both the efflux protein and the isoenzyme.

Coadministration may result in elevated loperamide plasma concentrations. Drugs with a possible risk for QT prolongation and TdP, like telavancin, should be used cautiously and with close monitoring with loperamide. Major Coadministration of loperamide with telithromycin may increase the risk for QT prolongation and torsade de pointes TdP.

Telithromycin is also associated with QT prolongation and torsades de pointes TdP. In addition, the plasma concentrations of loperamide, a CYP3A4 and P-glycoprotein P-gp substrate, may be increased when administered concurrently with telithromycin, a potent CYP3A4 and P-gp inhibitor, further increasing the risk of toxicity. Moderate Use caution if coadministration of telotristat ethyl and loperamide is necessary, as the systemic exposure of loperamide may be decreased resulting in reduced efficacy.

If these drugs are used together, monitor patients for suboptimal efficacy of loperamide; consider increasing the dose of loperamide if necessary. Moderate Use caution if coadministration of temsirolimus with loperamide is necessary, and monitor for an increase in loperamide-related adverse reactions.

Temsirolimus is a P-glycoprotein P-gp inhibitor in vitro, and loperamide is a P-gp substrate. Pharmacokinetic data are not available for concomitant use of temsirolimus with P-gp substrates, but exposure to loperamide is likely to increase. Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with testosterone, a P-gp inhibitor.

Tetrabenazine also has been associated with an increase in QT interval. The manufacturer of tetrabenazine recommends avoiding concurrent use of tetrabenazine with other drugs known to prolong the QTc interval.

Severe Thioridazine is associated with a well-established risk of QT prolongation and torsades de pointes TdP. The clinical significance of this interaction has not been established, and no recommendations for dosage adjustments are available. Moderate Loperamide should be used cautiously and with close monitoring with tizanidine. Tizanidine administration may result in QT prolongation and high doses of loperamide have been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes TdP , and cardiac arrest.

Moderate Loperamide should be used cautiously and with close monitoring with tolterodine. Tolterodine has been associated with dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers. High doses of loperamide have been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes TdP , and cardiac arrest.

Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with tolvaptan, a mild P-gp inhibitor. Drugs with a possible risk for QT prolongation and TdP, like toremifene, should be used cautiously and with close monitoring with loperamide.

The manufacturer of trazodone recommends avoiding trazodone in patients taking other drugs that prolong the QT interval. Minor Trifluoperazine is associated with a possible risk for QT prolongation. Theoretically, trifluoperazine may increase the risk of QT prolongation if coadministered with drugs with a risk of QT prolongation.

Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with ulipristal, a mild P-gp inhibitor. Valproic Acid, Divalproex Sodium: Major The manufacturer of vandetanib recommends avoiding coadministration with other drugs that prolong the QT interval due to an increased risk of QT prolongation and torsade de pointes TdP ; there is also a possible increase in loperamide-related adverse reactions.

Vandetanib can prolong the QT interval in a concentration-dependent manner. TdP and sudden death have been reported in patients receiving vandetanib. If coadministration is necessary, an ECG is needed, as well as more frequent monitoring of the QT interval. If QTcF is greater than msec, interrupt vandetanib dosing until the QTcF is less than msec; then, vandetanib may be resumed at a reduced dose.

Additionally, loperamide is a partial substrate of P-glycoprotein P-gp. Drugs with a possible risk for QT prolongation and TdP, like vardenafil, should be used cautiously and with close monitoring with loperamide. Major Loperamide should be used cautiously and with close monitoring with vemurafenib. Vemurafenib has been associated with QT prolongation. If vemurafenib and loperamide must be coadministered, ECG monitoring is recommended; closely monitor the patient for QT interval prolongation.

In addition, the plasma concentrations of loperamide, a CYP2D6 and P-glycoprotein P-gp substrate, may be increased when administered concurrently with vemurafenib, a CYP2D6 and P-gp inhibitor, further increasing the risk of toxicity.

Moderate Loperamide should be used cautiously and with close monitoring with venlafaxine. Venlafaxine administration is associated with a possible risk of QT prolongation; TdP has reported with post-marketing use. Coadministration may increase the risk for QT prolongation and TdP.

In addition, the plasma concentrations of loperamide, a CYP2D6 substrate, may be increased when administered concurrently with venlafaxine, a weak CYP2D6 inhibitor, further increasing the risk of toxicity. Major Caution is advised when administering voriconazole with drugs that are known to prolong that QT interval and are metabolized by CYP3A4, such as loperamide.

Voriconazole has been associated with QT prolongation and rare cases of torsades de pointes TdP ; at high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest.

In addition, coadministration of voriconazole a CYP3A4 inhibitor with loperamide a CYP3A4 substrate may result in elevated loperamide plasma concentrations and could increase the risk for adverse events, including QT prolongation. Rigorous attempts to correct any electrolyte abnormalities i. Moderate Loperamide should be used cautiously and with close monitoring with vorinostat. Vorinostat therapy is associated with a risk of QT prolongation and high doses of loperamide have been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes TdP , and cardiac arrest.

Coadministration may further increase the risk for QT prolongation and TdP. In one study, ziprasidone increased the QT interval 10 msec more than placebo at the maximum recommended dosage.

Comparative data with other antipsychotics have shown that the mean QTc interval prolongation occurring with ziprasidone exceeds that of haloperidol, quetiapine, olanzapine, and risperidone, but is less than that which occurs with thioridazine. Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with zonisamide, a mild in vitro inhibitor of P-gp.

Animal reproduction studies with rats and rabbits, up to 30 times human doses, have not demonstrated impaired fertility, teratogenicity, or fetal harm. One prospective, controlled surveillance study involving newborns exposed to loperamide during gestation reported 6 5.

The authors concluded that the drug was likely not associated with an increased risk of major malformations. In a different epidemiologic study 43 cases of women reporting the use of loperamide in early pregnancy were compared with a control group.

The authors concluded that there may be moderate risks in infants exposed to loperamide in early pregnancy. There are no adequate and well-controlled studies in pregnant women. Loperamide should be used with caution during pregnancy and only when the potential maternal benefit outweighs any potential fetal risk.

As with all medications, women should consult their health care professional prior to self-treatment during pregnancy. While manufacturers do not recommend loperamide use during lactation ; the American Academy of Pediatrics generally considers the use of loperamide compatible with breast-feeding as use during lactation is unlikely to adversely affect the infant.

Small amounts of loperamide may appear in human breast milk, based on data of the excretion of loperamide in human breast milk at low levels following use of a prodrug, loperamide oxide. As with all medications, women should consult their health care professional prior to self-treatment during lactation.

Loperamide interferes with peristalsis by a direct action on the circular and longitudinal muscles of the intestinal wall to slow motility. By increasing the transit time of the intestinal contents, loperamide reduces fecal volume, increases the bulk density and the viscosity of the feces, and decreases the loss of electrolytes and fluids from the body.

Sign up for email

These increases were not associated with central nervous system CNS effects as measured by psychomotor tests i, loperamide hcl capsules 2mg. In addition, the plasma concentrations of loperamide, a CYP3A4 substrate, may be increased capsule administered concurrently capsule dasatinib, 2mg weak CYP3A4 inhibitor, further increasing loperamide risk of toxicity. Loperamide is metabolized by the hepatic enzyme CYP3A4, and is a substrate for hcl drug transporter Loperamide P-gp. An interruption of crizotinib therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib patients if QT prolongation occurs. Hcl Loperamide should be used cautiously and capsule close monitoring with metronidazole. If responsive to naloxone, vital signs must be monitored carefully for recurrence of symptoms of drug overdose loperamide at least 24 2mg after the last dose of naloxone. Moderate The plasma concentration and efficacy of loperamide may 2mg reduced when administered concurrently with phenytoin or hcl. Constipation and dry mouth are reported side effects of fesoterodine, loperamide hcl capsules 2mg. Moderate Monitor for an increase in loperamide-related adverse reactions, including CNS and cardiac reactions, if coadministration with everolimus is necessary.

Loperamide (Imodium) and Heart Problems!

LOPERAMIDE 2MG CAPSULES

Other drugs that also decrease GI motility, such as amoxapine, may produce additive effects with antidiarrheals if 600mg fluvoxamine concomitantly. The adverse events reported are summarized irrespective of the causality assessment of the investigators. Monitor for cardiac toxicities i. Clinically relevant QTc prolongation buy abilify injection us occur with deutetrabenazine. Major Caution is advised when administering voriconazole with drugs that are known to prolong that QT interval loperamide are metabolized by CYP3A4, such as loperamide. Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with lovastatin, a P-gp inhibitor. Moderate The plasma concentration of loperamide, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with suvorexant, a 2mg inhibitor, loperamide hcl capsules 2mg. Animal reproduction studies with rats and rabbits, up to 30 times human doses, have not demonstrated hcl fertility, teratogenicity, or fetal harm. Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin. Moderate Antidiarrheals can decrease GI motility and may antagonize the effects of drugs used to treat constipation, such as linaclotide. Major Coadminister chloroquine with other drugs known to prolong the QT interval, such as loperamide, with caution. Moderate Pharmacodynamic interactions between loperamide and drugs that enhance peristalsis are theoretically possible. Severe Dronedarone administration is associated with a dose-related increase in the QTc interval. Minor Coadministration of loperamide with beta-agonist may increase the capsule for QT prolongation and torsade de pointes TdP. Major Loperamide should be used cautiously and with close monitoring with propafenone.

loperamide imodium

Tags: cozaar generic price oxycodone retail price buy prilosec online canada

© Copyright 2017 Loperamide hcl capsules 2mg *** morbidevoci.ch.